Voice your opinion on congressional bill HR5882-116 and let lawmakers know your stance with UnPac!

Main Subject: Health

Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act

This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.

HR19-116, S2543-116, S4199-116,

House floor actions Actions

IntroReferral
Feb. 12 2020	Referred to the House Committee on Energy and Commerce.

Library of Congress Actions

IntroReferral
Feb. 12 2020	Introduced in House Introduced in House

House bill HR5882-116

To amend title XIX of the Social Security Act to provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements, and for other purposes.

House bill HR5882-116

To amend title XIX of the Social Security Act to provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements, and for other purposes.

Promote the cause!

Or use this QR code